Morgan Stanley Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $758.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by equities research analysts at Morgan Stanley from $730.00 to $758.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price would suggest a potential upside of 0.54% from the company’s current price.

Several other brokerages also recently issued reports on REGN. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. TD Cowen upped their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Cantor Fitzgerald increased their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday. Truist Financial raised their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Leerink Partners restated a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $793.12.

Regeneron Pharmaceuticals Trading Up 2.1%

Shares of REGN traded up $15.60 during midday trading on Friday, hitting $753.94. The stock had a trading volume of 409,589 shares, compared to its average volume of 856,290. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $821.11. The firm has a market cap of $79.71 billion, a PE ratio of 18.36, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock’s 50 day moving average is $640.66 and its 200 day moving average is $711.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the business earned $12.81 EPS. The business’s revenue was up 16.7% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals will post 2.06 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wedge Capital Management L L P NC increased its holdings in Regeneron Pharmaceuticals by 20.3% during the second quarter. Wedge Capital Management L L P NC now owns 47,775 shares of the biopharmaceutical company’s stock valued at $29,790,000 after buying an additional 8,063 shares during the period. Insight Wealth Strategies LLC lifted its holdings in Regeneron Pharmaceuticals by 26.9% during the second quarter. Insight Wealth Strategies LLC now owns 8,734 shares of the biopharmaceutical company’s stock worth $5,456,000 after buying an additional 1,850 shares during the period. Tema ETFs LLC lifted its holdings in Regeneron Pharmaceuticals by 2.3% during the second quarter. Tema ETFs LLC now owns 5,481 shares of the biopharmaceutical company’s stock worth $3,418,000 after buying an additional 121 shares during the period. E. Ohman J or Asset Management AB boosted its position in Regeneron Pharmaceuticals by 35.2% during the 2nd quarter. E. Ohman J or Asset Management AB now owns 3,840 shares of the biopharmaceutical company’s stock valued at $2,394,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Harrell Investment Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 2nd quarter. Harrell Investment Partners LLC now owns 2,089 shares of the biopharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 27 shares during the period. Institutional investors own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Significant Q2 earnings beat: Regeneron reported non-GAAP EPS of $14.29, well above the $10.16 consensus estimate, while revenue rose 16.7% year over year to $4.29 billion versus expectations of $3.82 billion. Record demand for Dupixent and EYLEA HD drove the performance. Reuters earnings report
• Positive Sentiment: Growth across key products: Dupixent sales increased 38% to a record $6.0 billion, EYLEA HD U.S. sales climbed 52% to $596 million, and Libtayo sales rose 30% to $489 million. The results helped offset declines in older EYLEA sales and competitive pressures. Regeneron Q2 results
• Positive Sentiment: Analyst targets increased: Cantor Fitzgerald raised its target from $750 to $795 and maintained an overweight rating. Truist also lifted its target from $769 to $772 while retaining a buy rating. Benzinga analyst updates
• Neutral Sentiment: Limited Wells Fargo upside: Wells Fargo raised its target from $700 to $750 but kept an equal-weight rating, signaling that the firm sees relatively modest additional upside at recent trading levels. Benzinga Wells Fargo update
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, although the approximately 0.5% yield is unlikely to be a major stock catalyst. The company also announced its annual $150,000 prize for early-career scientists.
• Negative Sentiment: Ongoing litigation over failed melanoma trial: Multiple law firms are promoting a securities class action alleging that Regeneron misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo trial, which ultimately failed. The litigation and September 14, 2026 lead-plaintiff deadline remain sources of legal and reputational risk. Hagens Berman litigation alert

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.